Rating on Natera (NASDAQ:NTRA) is Outperform. Its Reconfirms by Baird with $20 Target.

June 29, 2018 - By Michael Higginson

Natera, Inc. (NASDAQ:NTRA) Corporate Logo

Reiterated Natera (NASDAQ:NTRA) Rating.

On Thursday morning Baird have a $20 TP on Natera (NASDAQ:NTRA). A upside potential of 4.22 % have this TP. The $1.05B market cap company have Outperform stock rating disclosed in an analyst note.

Natera, Inc. (NASDAQ:NTRA) Ratings Coverage

A total of 4 analysts rate Natera (NASDAQ:NTRA) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:NTRA) has 8 ratings reports on Jun 29, 2018 according to StockzIntelligence. The stock rating was maintained by Morgan Stanley with “Overweight” on Monday, June 25. On Friday, June 22 the stock of Natera, Inc. (NASDAQ:NTRA) has “Buy” rating given by Craig Hallum. On Wednesday, March 14 the firm has “Buy” rating by Robert W. Baird given. The stock rating was maintained by Robert W. Baird with “Outperform” on Thursday, June 28. On Wednesday, May 9 the rating was maintained by Morgan Stanley with “Overweight”. On Wednesday, March 14 the firm has “Buy” rating given by Canaccord Genuity. On Monday, June 25 the stock has “Buy” rating by Canaccord Genuity.

NTRA reached $19.19 during the last trading session after $0.22 change.Currently Natera, Inc. is uptrending after 12.60% change in last June 29, 2017. NTRA has 209,466 shares volume. NTRA outperformed the S&P500 by 0.03%.

Natera, Inc. (NASDAQ:NTRA) is anticipated to reveal earnings on August, 14., according to RTT. Analysts forecast 1.92 % diference or $-0.53 from the $-0.52 EPS from 2017. Wall Street forecasts -13.11 % EPS growth as of August, 14.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services.The firm is worth $1.05 billion. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.Last it reported negative earnings. The firm also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

For more Natera, Inc. (NASDAQ:NTRA) news posted briefly go to: Benzinga.com, Benzinga.com, Fool.com, Benzinga.com or Benzinga.com. The titles are as follows: “42 Biggest Movers From Yesterday” posted on June 28, 2018, “40 Stocks Moving In Wednesday’s Mid-Day Session” on June 27, 2018, “Why Natera Inc. Is Rising Today” with a publish date: June 25, 2018, “44 Biggest Movers From Yesterday” and the last “50 Biggest Movers From Friday” with publication date: June 25, 2018.

Natera, Inc. (NASDAQ:NTRA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: